Arsanis Secures $12,999,999 New Funding

  • Feed Type
  • Date
    8/13/2013
  • Company Name
    Arsanis
  • Mailing Address
    16 Cavendish Court Lebanon, NH 03766
  • Company Description
    Arsanis is committed to the development of fully human monoclonal antibodies against severe infectious diseases for which current prophylactic or therapeutic approaches are ineffective or non-existent.
  • Website
    http://www.arsanis.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,999,999
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Not a solicitation.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.